Market Research Reports Global Blood Plasma Products Market | Page 2

operative risks associated with albumin-based therapy may hamper the market growth. Albumin market
share is followed by hyperimmune globulin, coagulation factor VIII, and coagulation factor IX in 2018.
On the basis of end users, the hospital segment dominated the market with a market share of ~82% in
2018. This is due to the increase in the number of hospitals in developing countries and the rise in
awareness of diseases like hemophilia. It is followed by clinics with a market share of 14.1% in 2018. The
clinics market is driven by the growing number of clinics, increase in awareness among patients
regarding plasma products and rise in the number of patients with blood and immunological disorders.
Other end users that include research institutes, blood transfusion centers, and academic institutes was
having the least market share in 2018.
Regional insights
North America is leading the blood plasma products market and occupied approximately 44.2% of the
market in 2018. This is due to the rising incidence of haemophilia, and rapid approval by the FDA for the
plasma products. Europe is likely to expand over the forecast period of 2018-2023, by exhibiting a CAGR
of 6.6%. This is due to easy access to high-quality plasma through the contributions of qualified donors.
Europe is followed by the Asia pacific with a market share of 19.3% in 2018. India and China are the
major contributors of plasma products market in the Asia-Pacific region due to a large number of
immunodeficient patients to get treated in hospitals and clinics. The Latin America and the Middle-East
and Africa markets though, still at nascent stages, will also experience high growth because of the
growing prevalence of blood disorders.
MajorPlayers profiled in the Blood Plasma Products Market report incorporate: CSL Behring, Shire Plc,
Grifols S.A, Octapharma AG, ADMA Biologics, KedrionBiopharma
Latest Industry News
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world’s three top providers of plasma-
derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin
sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to
provide plasma-protein-based solutions to manage surgical bleeding.
Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is
administered with Ethicon’s airless spray device technology.
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on
“Global Blood Plasma Products Market Report 2019” @
https://www.businessindustryreports.com/buy-now/174445/single .
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.